2021 Vitiligo International Symposium – Khaled Ezzedine, MD, PhD

Title

Efficacy and Safety of the Oral Janus Kinase 3/Tec Inhibitor Ritlecitinib (PF-06651600) In Adults With Active Non-segmental Vitiligo: Results From a Phase 2b, Randomized, Dose-Ranging Study With an Extension Period